Add BrightSurf on Google Email

Trinity researchers publish ‘playbook’ for understanding pancreatic cancer, one of the deadliest cancers

Researchers at Trinity College Dublin have published a comprehensive review of pancreatic cancer, explaining why it's resistant to treatment and where new hope may emerge. The study identifies multiple biological systems interacting to drive the disease's growth and suggests combination-based treatments targeting multiple hallmarks of ...

SourceTrinity College Dublin·JournalCancer Letters·TypeNews article·DateMay 6, 2026

Brain structure differences may explain striking ancestry gaps in blood cancers

A new study reveals that specific features of the human cerebral cortex are causally linked to multiple myeloma and chronic lymphocytic leukemia, differing between ancestries. Genetic variants favoring larger pars triangularis surface area and thicker frontal cortices are found in Western populations.

SourceEditorial Office and Clinical Cancer Bulletin·JournalClinical Cancer Bulletin·TypeData/statistical analysis·DateApr 29, 2026

New awards and publications showcase achievements from staff at the National Comprehensive Cancer Network

NCCN staff received awards and publications for advancing quality cancer care, including Dr. Alyssa Schatz's Leadership in Policy, Equity, and Advocacy award and Faviolla Baez-Cruz's publication on biochemical research. The National Comprehensive Cancer Network is recognized for its work to improve outcomes for people with cancer.

Why cell therapy cancer treatment sometimes fails

Researchers found that patients with high senescence burdens in their CD8+ T cells were more likely to fail treatment, while those with youthful profiles responded better. The study identified three transcription factors controlling the senescence program, which can be targeted to improve treatment outcomes.

SourceRutgers University·JournalCell Reports·DateApr 29, 2026

Living longer with less burden of cancer treatment: new endpoints defined for cancer trials

A new paradigm shift in cancer research defines valid primary study endpoints for oligometastatic disease, focusing on treatment-free time and minimal side effects. The consensus paper establishes two new metrics: STFS (Start or Switch of Systemic Therapy–Free Survival) and pPFS (polymetastatic Progression–Free Survival), which capture...

SourceMedical University of Vienna·JournalThe Lancet Oncology·TypeSystematic review·DateApr 28, 2026

26 Years of development of EGFR-TKIs for non-small cell lung cancer: Clinical application and resistance research progress

EGFR-TKIs have significantly improved OS and quality of life for EGFR-mutant NSCLC patients. However, ongoing research is needed to refine therapies for precise individualized treatment, addressing resistance mechanisms and optimal combination strategies.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateApr 28, 2026

Bowel and ovarian cancer cases rising among younger adults in England

Cancer cases are on the rise among younger adults in England, with a significant increase in bowel and ovarian cancer rates. The study found that excess weight is a key contributor, but it's unlikely to fully explain this trend, as trends in risk factors such as smoking and diet have been stable or improving over the past decade.

SourceBMJ Group·JournalBMJ Oncology·TypeData/statistical analysis·DateApr 28, 2026

AI tool that estimates biological age from face photos could serve as prognostic biomarker for cancer

A new study suggests that an AI tool analyzing facial changes can serve as a prognostic biomarker for cancer prognosis. The researchers found that patients with higher biological aging rates had lower chances of survival, and the effect was strongest when photos were taken over longer intervals.

SourceMass General Brigham·JournalNature Communications·TypeComputational simulation/modeling·DateApr 28, 2026

Drugging the undruggable: Scientists achieve million-fold leap in targeting elusive cancer proteins

Researchers at the University of British Columbia have developed a new method to target intrinsically disordered proteins, which are difficult to treat with medication. The approach has shown promise in slowing prostate cancer growth and could lead to new treatments for various diseases.

SourceUniversity of British Columbia·JournalSignal Transduction and Targeted Therapy·TypeExperimental study·DateApr 27, 2026

Unleashing natural killer cells against cancer

Scientists have developed a strategy to enhance the cancer-fighting power of natural killer cells by suppressing specific proteins. This approach effectively kills human cancer cells across several hard-to-treat tumour types, including leukemia and triple-negative breast cancer.

SourceMcGill University·JournalEMBO Reports·TypeExperimental study·DateApr 24, 2026

Stiffer tumor tissue causes cancer to spread more quickly

Research from Lund University reveals that stiffer tumor tissue triggers a chain of molecular events driving cancer cells to invade surrounding tissue. The studies identified key proteins and pathways involved in this process, offering new insights into the mechanical properties of tumor microenvironments.

SourceLund University·JournalAdvanced Science·TypeExperimental study·DateApr 23, 2026

New targeted therapy shows promise against aggressive childhood and adult cancers

A new targeted therapy has shown strong results in preclinical studies against aggressive childhood and adult cancers, eliminating tumours and stopping cancer spread. The therapy targets the IL1RAP protein, which is found on cancer cells but largely absent from normal tissues, allowing for precise delivery of treatment.

SourceUniversity of British Columbia·JournalCancer Discovery·TypeExperimental study·DateApr 23, 2026

Wayne State University and Barbara Ann Karmanos Cancer Institute researchers establish new digital engagement and cancer outcomes center with ACS grant

Researchers will build connections with Detroit's digital equity ecosystem and promote digital inclusion to link cancer patients, survivors, and caregivers with resources. The Digital Engagement and Cancer Outcomes (DECO) Center aims to advance interventions that improve outcomes at the individual level.

Immunotherapy shows early promise in sparing cancer patients from bladder removal

A phase 2 study led by NYU Langone Health showed that adding pembrolizumab to standard chemotherapy and radiation with surgery allowed 60% of patients to avoid bladder removal for up to two years post-treatment. This breakthrough treatment offers hope to patients with muscle-invasive urothelial cancer of the bladder.

SourceNYU Langone Health / NYU Grossman School of Medicine·JournalEuropean Urology·TypeRandomized controlled/clinical trial·DateApr 22, 2026

Deceptive ovarian cancer case mimics pelvic abscess, delaying diagnosis in postmenopausal woman

A rare case of mucinous ovarian carcinoma was reported in a postmenopausal woman, initially misdiagnosed as a pelvic abscess due to nonspecific symptoms and radiologic features. The diagnosis was confirmed after advanced imaging and tumor marker assessment. Early recognition is crucial for timely diagnosis and effective treatment of th...

SourceImpact Journals LLC·JournalOncoscience·TypeCase study·DateApr 22, 2026

Cellular neighborhoods inside tumors may predict which patients with melanoma benefit from combination immunotherapy

Researchers found that tumor genetics alone did not explain which patients responded to combination therapy, but rather the tumor's immune environment. Patients with active networks of cancer-killing T cells were more likely to benefit from treatment, while those with dense clusters of plasma cells were less likely.